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In individuals with brain tumors, pharmacodynamic and
pharmacokinetic studies of therapeutic agents have histori-
cally used analyses of drug concentrations in serum or cere-
brospinal fluid, which unfortunately do not necessarily
reflect concentrations within the tumor and adjacent brain.
This review article introduces to neurological and medical
oncologists, as well as pharmacologists, the application of
microdialysis in monitoring drug metabolism and delivery
within the fluid of the interstitial space of brain tumor and
its surroundings. Microdialysis samples soluble molecules
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from the extracellular fluid via a semipermeable membrane
at the tip of a probe. In the past decade, it has been used pre-
dominantly in neurointensive care in the setting of brain
trauma, vasospasm, epilepsy, and intracerebral hemorrhage.
At the first Carolyn Frye-Halloran Symposium held at
Massachusetts General Hospital in March 2002, the con-
cept of microdialysis was extended to specifically address its
possible use in treating brain tumor patients. In doing so we
provide a rationale for the use of this technology by a Na-
tional Cancer Institute consortium, New Approaches to Brain
Tumor Therapy, to measure levels of drugs in brain tissue as
part of phase 1 trials. Neuro-Oncology 6, 65–74, 2004 (Posted
to Neuro-Oncology [serial online], Doc. 03-010, Novem-
ber 21, 2003. URL http://neurooncology.mc.duke.edu;
DOI: 10.1215/S1152 8517 03 00010 3)
Therapeutic approaches to malignant brain tumorsimpose significant constraints upon the cliniciansand basic scientists designing therapy for brain
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tumor patients. Although surgical resection and radiation
therapy are paramount to local control of the disease,
microscopic foci of infiltrating tumor cells appear resist-
ant to both interventions, which spur the use of adjuvant
regimens of chemotherapy. Despite the logical selection
of these drugs using preclinical screens of molecular and
enzymatic targets, the past 3 decades have offered no
improvement in the survival for patients with malignant
brain tumors (DeAngelis, 2001; Dropcho, 2001). The
lack of efficacy of therapies is all the more surprising in
an era that has contributed to “rational drug design” for
brain tumor therapies, administration and drug sched-
ules to maximize brain penetration, and awareness of the
powerful role of cytochrome P450 induction on the acti-
vation of brain tumor-specific agents. 
Irrespective of location or histology, drug delivery is a
critical determinant of successful chemotherapy. The
blood-brain barrier (BBB)2 raises obstacles to drug deliv-
ery to brain tumors. Most drugs administered systemi-
cally for the treatment of brain tumors have properties
that promote passage across the barrier such as low
molecular weight (200 Da), lipophilicity, and low protein-
binding capability (Rall and Zubrod, 2000). It is likely
that the barrier is disrupted in a nonhomogeneous fash-
ion, permitting the passage of some agents (bleomycin,
nitrosoureas, and platinum compounds) into tumors
(Hargrave et al., 2002; Korppi-Tommola et al., 1999;
Roche et al., 2000; Ryynanen et al., 1998; Tokunaga et
al., 2000). The techniques used to show brain delivery of
these compounds involve tissue analyses from biopsies,
which provide minimal data concerning distribution
kinetics or activated drug levels within tumor and/or its
distant infiltrates. These issues are crucial to our under-
standing of the anticancer agents within brain tumors
after administration by various routes, including systemic
delivery (Cairncross et al., 2000; Graham et al., 1997;
Kraemer et al., 2002), direct bolus injection into tumor
(Boiardi et al., 1999; Disabato et al., 1999), intrathecal
or intraventricular convection-enhanced parenchymal
delivery (Bobo et al., 1994), or local implants (Lesniak et
al., 2001). The last 2 techniques provide local therapies
that emphasize drug diffusion driven by gradients in drug
concentration or hydrostatic pressure. These techniques
underscore the need for novel analytic strategies to mea-
sure drug concentrations within selected areas of brain.
Preclinical and phase 1 studies of anticancer drugs rely
on animal models and surrogate measures of drug activ-
ity. When clinicians relate drug dose to drug effect, dose
is the surrogate for concentration of activated drug
assumed at the effector tumor site. Akin to this is the
assumption that drug concentration within tumor is pro-
portional to dose (Kellie et al., 2002; Koopmans, 2002).
In pharmacokinetic (pK) studies, drug effects either are
related to their plasma concentrations over time or are
expressed as integrated effects of drug exposure (area
under the concentration  time curve [AUC]), clearance,
volume of distribution, and half-life (Gibaldi and Perrier,
1982). This assumes a measurable relation between
plasma levels and concentration at the effector site (Lowe
and Balis, 2001). Uncertain is whether tissue homogenates
provide accurate measurement of integrated drug con-
centrations. These studies provide data at a single time
point, from both vascularized and necrotic tumor tissue.
Most important for clinical phase 1 trials are the differ-
ences in tumor exposure due to the intra- and interpa-
tient variability observed in pK studies. 
Recent advances in anticancer drug development have
shifted from cytotoxic antimitotic agents in favor of
agents that target specific points in the cell cycle or inter-
fere with pathways of signal transduction. These thera-
pies are cytostatic rather than cytotoxic. This shift in
therapies has introduced novel end points to replace “cell
kill” or tumor volume reduction on magnetic resonance
scans. Since serial tumor biopsies are not possible, sur-
rogate markers are obtained by other means, including
functional imaging studies, PET, dynamic enhanced MRI,
permeability maps, and MR spectroscopy. Validation of
these markers will require that traditional pK analyses
and imaging end points be coupled to the development
of in situ pK and pharmacodynamic analyses in future
trials (Chabner et al., 1998; Fox et al., 2002a). Imple-
mentation of these analyses in clinical trials will require
minimally invasive techniques. Microdialysis, an evolv-
ing sampling technique suited for in vivo pK and phar-
macodynamic studies in tumor tissue, was introduced in
1974 to monitor neurochemical events in awake animals
(Ungerstedt and Pycock, 1974). The first human appli-
cation was published over a decade later, in 1987, mea-
suring interstitial glucose levels in adipose tissue (Lonn-
roth et al., 1987).
Since its introduction, the methodology has provided
quantitative end points in the clinical evaluation of head
trauma (Nilsson et al. 1996), stroke (Meixensberger et
al., 2001), epilepsy (During and Spencer, 1993), Parkin-
son’s disease (Meyerson et al., 1990), and brain tumors
(De Micheli et al., 2000; Roslin et al., 2003). Microdial-
ysis has also been proposed as a method of intratumoral
drug delivery. 
The application of microdialysis to neuro-oncology
was the subject of the First Annual Carolyn Frye-Halloran
Symposium held by New Approaches to Brain Tumor
Therapy consortium participants at the Massachusetts
General Hospital in March 2002. This article summa-
rizes the concepts and the preclinical and clinical appli-
cations of microdialysis presented at this conference.
Principles of Microdialysis
The technique of microdialysis makes use of an im-
planted probe communicating by diffusion with the
brain’s extracellular space. A microsyringe pumps a solu-
tion (perfusate) into the proximal end of the cannula of
a cylindrical probe. The perfusate flows distally to the
semipermeable polymeric membrane (typically 5 to 20
kDa in pore size). There, solutes within the perfusate dif-
fuse from the perfusion solution to the interstitium. At
the same time, molecules from the extracellular fluid dif-
fuse inward. In essence, an artificial capillary is created,
albeit one that is more than 10 times the width of a cor-
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tical vessel (Fig. 1) but one that has predictable diffusion
characteristics (Elmquist and Sawchuk, 1997).
The analyte of interest is collected at regular intervals
and analyzed at the bedside or in the laboratory. When
microdialysis is used to sample the analyte from the
extracellular fluid (ECF), the concentration of analyte
in the dialysate is usually less than the concentration sur-
rounding the probe membrane. Thus, the dialysate con-
centration relates to a fraction of that in the ECF. The
ratio between the analyte in the tube and that in the
extracellular space, or fractional recovery, provides an
indirect measure of the concentration within the extra-
cellular space. The movement by diffusion of analyte is
from areas of high concentration to those of low con-
centration across a gradient created by the high concen-
trations within tissue ECF and lower concentrations
within the perfusing solution of the microdialysis probe
(Fig. 2).
Microdialysis sampling differs from that in conven-
tional pK studies, which produce data at discrete time
points. The dialysate is continuously collected. In pK
transients, continuous collection produces an analyte
concentration that is averaged over the sampling inter-
val, thus reflecting an AUC integration. For linear sys-
tems, the dialysate AUC can be corrected by steady-state
calibration to yield the AUC in the ECF (Bungay et al.,
2001; Elmquist and Sawchuk, 1997).
Numerous factors influence the relationship between
dialysate and ECF concentrations. Raising the perfusate
flow rate lowers the concentration of analyte in the
dialysate samples. Thus, fractional recovery is decreased
as the perfusate flow rate is increased. This favors the use
of slow perfusate flows, but then longer sampling inter-
vals tend to be necessary to generate sufficient dialysate
to assay. Alternatively, higher dialysate analyte concen-
trations can be promoted by lengthening the dialysis
membrane. This factor is constrained by the dimensions
of the tissue volume to be probed. Stated differently, slow
perfusion and long probes promote equilibrium between
outflow dialysate and surrounding extracellular fluid, as
illustrated in the following formula for analyte recovery
(Ed):
Ed =
Coutd
Cappe
➝  1
Drug concentrations:
Coutd = in outflow dialysate
Cappe = in sampling volume of extracellular fluid
When equilibrium is not achieved, Ed is a direct function
of the rate of analyte clearance from the ECF (Sun et al.,
2001), along with many other parameters, such as the
perfusate flow rate, diffusion coefficients, geometry of the
probes, and the extracellular volume. Many of these
parameters are not well known. Determining the ECF
concentration then requires calibration to evaluate the
fractional recovery. Empirical approaches have been
developed for probe calibration when the ECF concen-
tration does not vary over time. The “no-net-” or “zero-
net-flux” technique involves perfusing the probe succes-
sively with solutions containing the analyte at different,
known concentrations. “No-net flux” refers to the situ-
ation in which the outflow dialysate concentration is the
same as the inflow perfusate concentration (Lonnroth et
al., 1987). This concentration is presumed to equal the
ECF concentration and can be calculated by interpola-
tion (Fig. 3). 
Retrodialysis is an alternative steady-state calibration
technique that makes use of a calibrator (an analog of the
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Fig. 1. Microdialysis probe. Left panel. The probe inserted into the brain and its laboratory components. Right panel. Probe width with respect to
a cortical blood vessel. The length approximates 10 mm in actuality. The bar at lower left of the panel indicates 500 m.
analyte of interest), which is added to the perfusate
(Wang et al., 1993). Probe calibration under conditions
of time-varying ECF concentrations is more problematic
(Bungay et al., 2001). Where feasible, maintaining the
recovery close to 100% at all times by slow perfusion is
an approach to avoiding the difficulties of calibration. 
Application of Microdialysis
Animal Studies
Studies with rodents have been used to demonstrate the
utility of microdialysis techniques for the measurement
of active metabolites of drugs in brain tissue. These stud-
ies have made use of platinum compounds, methotrexate
(MTX), angiogenesis inhibitors, and cytokines. One such
example is the measurement of platinum and its DNA
adducts in mice bearing flank B16 murine melanoma and
non-small cell lung cancers, after the delivery of either
cisplatin or liposomal (SPI-077 Stealth [Sequus Pharma-
ceuticals, Menlo Park, Calif.]) cisplatin (Zamboni et al.,
2002). In this study, a 4-mm-long, 0.5-mm-wide probe
was inserted into the tumor bed, and dialysate samples
were obtained every 12 min. The plasma concentration
of unbound cisplatin decayed rapidly, having a first-
phase half-life of 12 to 15 min and peak plasma concen-
tration of 15 min. Within both types of tumors tested,
drug decay was delayed. There was 10-fold intratumoral
concentration variability between mice. The liposomal
formulations provided 2.2- to 5-fold increase in the total
platinum within tumor compared with cisplatin alone,
but no platinum reached detectable concentrations in
ECF after liposomal delivery. The platinum adducts of
DNA were 3.5-fold higher after cisplatin than after lipo-
somal formulation. The researchers thus concluded that
liposomal formulation reached the tumor site at higher
doses than cisplatin, but it did not release the drug itself.
In a similar vein, the interaction between angiogene-
sis inhibitors and cytotoxic drugs has been shown by Gallo
and colleagues (Devineni et al., 1996a; Ma et al., 2001,
2003). The argument is that with successful antiangio-
genic treatment, the hyperpermeable tumor vasculature
can revert to normal, thus reducing the uptake of a co-
administered cytotoxic agent like temozolomide (TMZ).
In both syngeneic and xenograft brain-tumor models that
overexpressed vascular endothelial growth factor, TMZ
tumor concentrations were reduced following a thera-
peutic course of TNP-470. The reduced tumor concen-
trations of TMZ were ascribed to pharmacodynamic-
mediated changes of reduced microvessel density and
permeability by the antiangiogenic drug. By using
another, more specific vascular endothelial growth factor
inhibitor, SU5416, a contradictory effect occurred: TMZ
concentrations increased in brain tumors by 50%. It
appears that capillary density and permeability of the
tumor are not the only pharmacodynamic factors of
antiangiogenic effects, but blood flow, interstitial fluid
pressure, pH, and hypoxia may also play a vital role. 
Of potential interest to clinicians treating patients
who have brain lymphoma, subarachnoid cancer, and
glioblastoma, studies have made use of the hydrophilic
agent MTX (de Lang et al., 1995a; Devineni et al.,
1996b; Dukic et al., 1998). In prior studies cerebrospinal
fluid (CSF) concentrations reached 2% to 3% of injected
parenteral MTX concentrations, and administration into
the subarachnoid space or ventricles was fraught with
difficulties of uneven flow and drug sequestration. 
De Groot (unpublished data) has used male Fisher rats
and CMA-12 microdialysis probes (CMA Microdialysis,
North Chelmsford, Mass.). Microdialysis probes were
placed in the ventricular system, interstitial space, and
the thoracic drainage to identify the entry point of MTX.
The perfusate flow rate at 3 l/min provided sufficient
sample collections every 20 min. Drug concentration
plots from the 3 sites were superimposed without time
lag (Fig. 4), suggesting that intravenous MTX becomes
homogeneously distributed between CSF and brain ECF
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Fig. 2. Diffusion pattern. An analyte (white spheres) present in the
extracellular fluid (ECF) diffuses across the dialysis membrane (dashed
lines) to be collected in the dialysate, while a retrodialysis calibrator
solute (black spheres) entering the probe in the perfusate is delivered
to the ECF by diffusing in the opposite direction.
Fig. 3. Probe calibration by the no-net-flux technique involving mul-
tiple perfusions of the probe with solutions of varying analyte con-
centration. The fractional recovery is provided as the absolute value of
the slope. The extracellular concentration is estimated by interpolation
to the point indicated by the intersection of the perpendicular lines at
which the effluent dialysate concentration of the analyte is the same
as in the inflowing perfusate.
via capillaries, rather than from the choroid plexus.
The role of CSF in drug distribution appears to be
even more complicated. Although it has been assumed
that drug levels within CSF reflect brain concentrations,
this hypothesis has not been clearly tested. To determine
CSF penetration as a surrogate for brain penetration, Fox
and colleagues (2002b) at the National Cancer Institute
have studied concentrations of zidovudine in nonhuman
primates under steady-state (continuous infusion, n  5)
and transient (bolus dosing, n  3) conditions. Drug lev-
els were obtained from serum, CSF (Ommaya reservoir),
or subarachnoid space over the cortex, or by lumbar
puncture. Microdialysis probes (with a 10-mm-length 
0.5-mm-width probe membrane) were positioned in a
peripheral vein, temporalis muscle, and cerebral cortex.
CSF penetration was calculated as the ratio of free
zidovudine in CSF to that in serum for standard sam-
pling. CNS penetration was calculated as the brain
ECF/blood ECF ratio for microdialysis samples. Under
steady-state conditions (continuous infusion), the pene-
tration of zidovudine was similar in CSF and CNS, 17%
and 13%, respectively. The CSF penetration was compa-
rable to prior studies of zidovudine CSF penetration with
standard sampling. However, under transient conditions
(bolus dosing), the CSF penetration by standard sam-
pling methods was 28% compared to CNS penetration
of 18% using microdialysis. These data suggest that
zidovudine penetration of brain ECF and CSF is limited
by partitioning differences under transient conditions,
hypothetically related to saturation of active transport
mechanisms. This study included an analysis of micro-
dialysis recovery of analyte (Table 1). This was deter-
mined in vivo for each tissue using the zero-net flux
method (steady-state experiments) and by retrodialysis
(bolus experiments). Additionally, in vitro recovery was
determined for each probe at the conclusion of the in
vivo experiment to verify probe integrity. 
In summary, a few intriguing but unsettling issues can
be illustrated from the above animal studies. One is the
relationship between drug delivery and drug activity. As
shown in cisplatin studies, drug concentrations in the
extracellular space do not necessarily correlate with drug
uptake by tumor cells. The most that could be inferred is
that the drug has reached the vicinity of the tumor, in the
extracellular space; but it provides no information
regarding the intercellular physiology. The second issue
lies in parameters other than interstitial hydrostatic pres-
sure that may influence permeability through the micro-
dialysis membrane, such as the pH and level of oxy-
genation within the microenvironment being studied.
Perhaps of greater concern is an issue that arises from the
MTX study, whereby for those drugs that require capil-
lary distribution, any disruption to the capillaries can
lead to falsely elevated drug levels, which includes the
insertion of the microcatheter itself. 
Human Studies
Animal studies have demonstrated the safe use of dialy-
sis catheters for sampling from multiple tissues over time
points approaching several weeks. Cerebral monitoring
(having recently received FDA 510 (k) clearance) in
humans has extended these observations and demon-
strated both safety and ease of use of these systems.
Microdialysis catheters for sampling are routinely used
in centers from around the world, including Uppsala
(Sweden), Stockholm, London, Berlin, Richmond (Va.),
Houston (Tex.), Los Angeles (Calif.), Pittsburgh (Pa.),
Minneapolis (Minn.), and New Haven (Conn.), to name
a few. The microcatheters are visible on CT scans and
pose minimal invasive risks at implantation, sampling, or
removal (Fig. 5). Complications of bleeding or infection
equal the morbidity seen in stereotactic biopsy, cran-
iotomy, or intracerebral monitoring. 
Benjamin et al.: Microdialysis in brain tumors
Neuro-Oncology  JANUARY 2004 69
Table 1. Comparison of zidovudine recovery by microdialysis*      
Recovery
Blood Muscle Brain  
Method (Flow Rate) N  In Vitro In Vivo In Vitro In Vivo In Vitro In Vivo  
Zero Net Flux (1l/min) 5 Mean: 0.79 0.40 0.66 0.26 0.67 0.15     
SD: 0.11 0.29 0.12 0.11 0.06 0.07     
CV (%): 14 72 19 42 9 46
Retrodialysis (0.5 l/min) 3 Mean: 0.90 0.69 0.92 0.50 0.90 0.29     
SD: 0.07 0.06 0.06 0.10 0.05 0.10     
CV (%): 8 8 7 20 6 32  
Abbreviations used are as follows: CV, coefficient of variation; SD, standard deviation. 
* From Fox et al. (2002b). 
Fig. 4. Methotrexate concentration in the three CSF chambers.
M
et
ho
tr
ex
at
e 
co
nc
et
ra
tio
n 
(
g/
m
l)
Time (minutes)
The utility of the technique is most apparent in the
evaluation of changes after head trauma or subarachnoid
hemorrhage. In many institutions microdialysis catheters,
which could remain in place for up to 3 weeks, can pro-
vide continuous measures of brain biochemical changes.
In humans the basic rules apply: longer membranes and
lower flow rates yield greater relative recovery of analytes
into the dialysate. Tissue tortuosity shortens the diffusion
pathway and leads to decreased analyte recovery. Unlike
animal studies, however, some human studies have indi-
cated erratic results after day 7 of analyte recovery in
humans. The results may be secondary to in situ gliosis.
The extended experience from Uppsala of catheter use
in several hundred patients has been complemented by
the efforts of Goodman and co-workers at Baylor Col-
lege of Medicine. In the latter setting, probes were
implanted in 147 head-trauma patients for up to 5 con-
secutive days without complication. The microdialysis
catheters appear safer than intracranial pressure bolts
(Gopinath et al., 2002; Hlatky et al., 2002). (Some cen-
ters routinely administer prophylactic antibiotics to
retain a meningitis rate of 2%, which is similar to ven-
triculostomy.) Patients with poor outcome exhibit ele-
vated levels of excitatory amino acids, particularly aspar-
tate and glutamate (Vespa et al., 2003). Those with gross
tissue disruption typically have had the highest levels of
these amino acids. Similar data have been provided for
nitric oxide breakdown products of nitrate and nitrite,
which according to dialysate levels are lowest in patients
who expire shortly after head injury. Arguably, under-
standing prognostic factors after head trauma has proven
difficult, and in certain circumstances entirely paradoxi-
cal (Alessandri et al., 1999a,b). These include death or
vegetative state in the setting of normal intracerebral
pressure or unremarkable CT scans of the brain, or lack
of correlation between brain energy demands and de-
creased cerebral blood flow (Oertal et al., 2002). With
the aid of microdialysis, however, it has been shown that
favorable outcomes in traumatic brain are correlated
with lower levels of potassium and glutamate. Hyper-
ventilation therapy increases both extracellular lactate
and glutamate levels, accounting for its dire outcome
(Marion et al., 2002). Furthermore, such data underscore
the poor prognosis associated with low glucose levels and
elevated lactate, changes that are duplicated by PET stud-
ies (Vespa et al., 1998, 2003; Hutchinson et al., 2002).
Few data are available from studies of human tumors.
Epileptic patients with tumors often exhibit elevated lev-
els of excitatory amino acids during ictus, along with an
increase in lactate, pyruvate, and glycerol (reflective of
lipolysis). In fact, the seizure focus has markedly elevated
glutamate levels, by up to 10-fold. Since 1990, Spencer
and co-workers at Yale University have simultaneously
implanted 2 to 3 probes in more than 100 patients with
epilepsy as a result of brain tumor or cortical dysplasia.
Complications have not been observed during the 3-week
use of implanted probes, with flow rates at the time of
ictal events at 2.5 l/min. No evidence of bleeding or
infection has ever occurred in their cohort; the 5-kDa
membrane appeared to act as a barrier to pathogens and
microorganisms. The studies have demonstrated the het-
erogeneity of brain tumors and resulting seizures. For
instance, elevated glutamate levels were centered in
seizure focus in some, whereas GABA was more promi-
nent in others (Abi-Saab et al., 2002; During and Spencer,
1993).
A recent publication confirms the higher energy
demand by the tumor (Roslin et al. 2003). Microdialy-
sis analyses have indirectly shown the relatively lower
glucose (and higher lactate) levels within the interstitial
space fluid. Moreover, the necrotic tissue contains sig-
nificantly higher levels of glutamate.
The conclusions that can be drawn from human stud-
ies involving microdialysis are twofold: (1) The procedure
poses minimal risk in a mixture of neurological conditions
in awake and mobilized patients, but (2) there probably
exists interpatient variability, which complicates the appli-
cation of generalized results to any individual patient. In
brain tumor patients, the latter setback may perhaps be
downplayed since the major use of microdialysis would
be to analyze drug penetration or perform direct drug
infusion into the tumor bed. Nonetheless, a few signifi-
cant limitations cannot be ignored, and they are addressed
below.
Limitations and Benefits of Microdialysis
Animal and human studies raise several issues. As indi-
cated, the analyte recovery reflects the perfusate flow
rate. Lower flow rate yields higher recovery, but longer
sampling intervals. Even at high flow rates of 2 to 
3 l/min, it will require half an hour to collect 60-l sam-
ples for analysis. Recovery, even in trapping buffers, can
be sensitive to changes of temperature, minor movements
of the probe, and sample handling. Probe membrane per-
meability has not been tested for many drugs and their
active metabolites. Adsorption of interstitial macromol-
ecules to the probe membrane and gliosis can further
reduce permeability and diminish recovery. 
Diffusional exchange of solutes between the probe
and surrounding tissue (i.e., sampling or delivery of ana-
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Fig. 5. Microdialysis probe. A. Probe (arrow) in relation to bolt, intracra-
nial pressure monitor, brain O2 sensor; B. Probe as seen on CT scan
(arrow). C. Gliosis at the site of probe implant.
A.
C.
B.
lyte) creates spatial disturbances in the ECF concentra-
tion. This disturbance occurs over radial distances rang-
ing from micrometers to millimeters, depending upon the
avidity of clearance mechanisms for removing the solute
from the ECF (Bungay et al., 2001; Dykstra et al., 1992).
This distance corresponds at most to the width of a few
pixels on MRI; hence the disturbance would be difficult
to observe except by autoradiography. Stated differently,
the region of tissue affected by analyte sampling or deliv-
ery is variable depending upon the analyte, but rarely
extends greater than a couple of millimeters into the sur-
rounding tissue. The probe membrane length is a con-
sideration when compared to the size of anatomic struc-
tures such as tumor vasculature or tumor center versus
infiltrative margin. Accurate MRI-guided implantation
of the device by a skilled neurosurgeon is therefore nec-
essary.
Although dynamic microscopic interactions may alter
sample recovery, the system should still provide an order
of magnitude better resolution than currently provided
by MR spectroscopy, radiolabeled drugs for PET imag-
ing, or 3H-labeled drugs. The insertion of the device into
the brain tumor could be confirmed by any imaging stud-
ies. Multiple probes can be provided to sample micro-
scopic zones designated by MR spectroscopy, MR vas-
cular, or MR permeability studies. As the probe produces
minimal gliosis at the parenchymal site within 2 weeks of
use, study designs should provide drug levels for
lipophilic agents with long half-lives. The risk of com-
plicating hemorrhage, infection, or epilepsy is no greater
than the current intracerebral monitoring units. Studies
could be performed in freely moving animals or humans
and then during therapies that include combinations of
radiation and various cytotoxic and cytostatic agents. A
potential boon is the monitoring of transgene expression
rates for gene therapy trials in which proto-oncogenes
like TP53 and immunomodulators (interferon-) are
provided. Recently, interleukin-1, interleukin-6, and
nerve growth factor have been sampled in the interstitial
space fluid of patients with severe head trauma (Winter
et al., 2002). For all studies, drug concentrations from
brain tumor and surrounding tissue can be compared
with levels obtained from CSF and plasma. 
Other more serious limitations of microdialysis should
not be overlooked. One concern raised in the animal
studies is that BBB and its transcapillary transport sys-
tem can be disrupted by the simple insertion of the micro-
catheter, which may cause an overestimation of drug
uptake into the brain. In some studies the disruption may
persist for nearly a month (Groothuis et al., 1998; Mor-
gan et al., 1996; de Lang et al., 1995b). The disturbance
could result not only from direct tissue injury, but also
indirectly. It has been observed that matrix metallopro-
teinases are activated and released during probe inser-
tion, which leads to neutrophil infiltration and sub-
sequent tissue remodeling (Planas et al., 2002). The
greatest disruption appears after repeated microcatheter
insertions, however (de Lang et al., 1995b). Also, the
function of BBB is not significantly affected if surgical
conditions have been controlled (de Lang et al., 1997). In
brain tumors, blood-tumor barrier may already be com-
promised, as contrast-enhanced imaging studies attest.
More interesting, perhaps, is the recovery of the drug 
as an analyte by the probe, which depends on the con-
centration of the drug at that site and its metabolism, as 
well as its diffusion. If the first process of interstitial-
microvascular exchange could be estimated by micro-
dialysis, it would suggest nothing with respect to the
metabolism or diffusion of the drug. It is hoped that 
the preclinical experiments have already elucidated the
metabolism of the drug in hand. The major concern of
early clinical trials would therefore be to demonstrate
drug penetration. 
Conclusion
Evaluating the response of a particular therapy in pa-
tients with malignant gliomas poses many challenges and
difficulties. In phase 2 studies, outcome measurements
are usually based on progression-free survival at 6
months, and the measurements usually correlate with
neurological status or functional impairment. However,
most randomized trials of chemotherapy have fallen
short in showing a substantial benefit, and the new
agents that provide a slight improvement in survival in
phase 2 trials fail when tested in large randomized trials
(Brada and Shape, 1996; Brada and Yung, 2000; Haines,
2002). For example, microdialysis studies in individuals
with melanoma and breast cancer have shown no rela-
tion between serum concentrations of anticancer drugs
and tumor exposure to the drugs (Muller, 2000; Muller
et al., 1997).
The current trend by many neuro-oncologists is to fol-
low the stability or reduction in size of an enhancing
glioma on imaging studies after treatment. Ideally, this
may represent loss of tumor cells if there is a reduction,
which should be a reliable surrogate for cytotoxic agents.
However, the decrease in enhancement may also reflect a
change in properties of blood-brain or blood-tumor bar-
rier, undifferentiated by conventional MRI or CT scans
that do not rely on perfusion measurements or 3-D re-
construction analyses. These limitations are compounded
when therapy is provided in the setting of steroids, radi-
ation, or antiseizure medications. Furthermore, a large
percentage of high-grade gliomas display drug resistance
to numerous chemotherapeutic agents, and chemoresis-
tance profiles have been proposed to assist in treating
patients with such tumors appropriately, either in or out
of experimental trials (Haroun et al., 2002). Such drug
profiles can be performed in vitro easily, but are not as
practical because the specific tumor bioavailability, or
the fraction of the dose that gets to the tumor site, is not
known. Plasma or CSF concentrations of drugs and com-
pounds are typically used as substitutes of what actually
occurs within the tumor and the surrounding extracel-
lular fluid. In particular, active transport processes at the
level of blood-brain, blood-CSF, and blood-tumor bar-
riers lead to intricate relationships among concentrations
in plasma, CSF, and the tumor compartment.
Microdialysis could sidestep such indirect measure-
ments obtained by conventional methods. It has been
used to effectively detect short-term changes in excitatory
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and inhibitory amino acids, fatty acid amides, and other
endogenous substances within the interstitial fluid in a
variety of clinical settings, including epilepsy, stroke,
traumatic brain injury, and intracerebral hemorrhage.
The microcatheter can be easily implanted anywhere
within the cerebral cortex, hippocampus, pineal gland,
and even nucleus accumbens. The semipermeable mem-
brane of the probe measures only 10 mm in length and
500 m in width, but it is large enough to be visualized
on imaging studies. In addition to the feasibility of micro-
dialysis, it has other attractive advantages, including only
rare complications, “invasiveness” that is comparable to
other monitoring methods, and feasible bedside moni-
toring, as well as the capabilities to select specific analytes
to answer the questions at hand, monitor effects of treat-
ment, and study drug pKs and pharmacodynamics
within the extracellular space.
The last advantage leads to many promising and
potential uses for microdialysis. It may redefine phase 1
studies by detecting the presence of drug within the
tumor and thus guiding the continuation or discontinu-
ation of the drug for future phase 2/3 studies. This will
save the health care industry a great financial expendi-
ture and spare the patients from unnecessary exposure to
ineffectual drugs. Finally, the technique can be used not
only to continuously monitor the ECF concentration of
analytes, but also to deliver drugs to a specific tissue
region (retrodialysis), even though such a method could
face the same limitations that are faced by other in-
terventions such as brachytherapy and chemotherapy 
using impregnated wafers. The major difference, how-
ever, would be the length of treatment, which could be
extended by another week by continuous microdialysis
infusion. More importantly, drug-drug interactions could
be avoided, especially in the setting of P450-inducing
antiepileptics, and systemic complications and side effects
could be minimized. 
The trend in neuromonitoring until recently has been
to follow brain pO2, pCO2, pH, and temperature (see
Table 2). With the current microdialysis, amino acids and
ischemic markers could be monitored and might aid in
prognostication (Persson and Hillered, 1992).
The First Annual Carolyn Frye-Halloran Symposium
in March 2002 provided the platform for the use of
microdialysis in brain tumor patients. The symposium
illustrated the methodological concept of microdialysis
and its diverse uses in both animal and human studies.
To further advance this technology in the field of neuro-
oncology, a few points must be first clarified. Multicenter
trials using microdialysis monitors in the future should
consider a universal perfusion rate and perfusate, along
with the membrane permeability and the length of time
a probe can be inserted. Normal saline or a solution that
closely resembles CSF could be standardized to flow at
0.3 l/min for a fixed period of time before running into
interference and misinterpretation from the probe itself
as a result of gliosis or faulty calibration techniques. The
0.3-l/min rate is also ideal for application with the
CMA 600 bedside analyzer (CMA Microdialysis). How-
ever, the unique flow rate should be determined by the
recovery of the analyte of interest, the needed sample vol-
ume, and the expected concentration of analyte in the
ECF sampled. Other methods of analysis can be com-
bined with microdialysis to boost its sensitivity, such as
capillary electrophoresis and mass spectroscopy (Kennedy
et al., 2002). What must be emphasized is that the results
obtained with microdialysis should be compared with
results obtained with other in vivo techniques. For ex-
ample, perhaps microdialysis could be used to measure
choline:creatine ratio within a known malignant glioma
and to compare the results with those obtained concur-
rently from magnetic resonance spectroscopy. This will
minimize the natural tendency for errors to be accepted
as part of the methodology.
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Table 2. Trend in neuromonitoring
Neuromonitoring 10 to 15 years ago Neuromonitoring in 2002
Pressure Ventriculostomy Ventriculostomy, miniature transducer-tipped catheters
Flow CPP CPP Transcranial Doppler
Global CBF Global CBF Regional CBF Continuous local CBF
Kety-Schmidt Kety-Schmidt Stable Xe CBF TD-CBF
133Xe CBF 133Xe CBF SPECT Laser Doppler
PET
fMRI
Oxygenation SjvO2 Global O2 Regional O2 Local O2
CVP catheter SjvO2 NIRSO2 PbtO2
Fiberoptic catheter
Metabolism CSF Global Regional Local 
CSF PET Microdialysis
CMRO2,-G,-L pCO2, pH
Abbreviations used are as follows: CBF, cerebral blood flow; CMRO2,-G,-L, cerebral metabolic rate of oxygen, glutamate, lactate consumption; CPP, cerebral perfusion pressure; CVP,
central venous pressure; TD-CBF, transcranial Doppler – CBF; NIRSO2, near-infrared spectroscopy of oxygen saturation; PbtO2, brain tissue oxygen pressure; SjvO2, internal jugular venous
oxygen hemoglobin saturation.
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